IONS Research and Charts

IONS - Ionis Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-10-29 (Delayed quote data 2025-09-12)

Last 63.16	Change ⇓ -0.88 (-1.37%)	Volume 1,471,443
	Open 64.26	High 64.61	Low 63.07

8EMA (Daily) 59.70	40EMA (Daily) 48.16	50EMA (Daily) 46.62	STO (Daily) 95.532	MACD Hist (Daily) 3.205
8EMA (Weekly) 50.024	40EMA (Weekly) 40.25	50EMA (Weekly) 39.86	STO (Weekly) 87.647	MACD Hist (Weekly) 4.825


Company Profile
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.